Celltrion's subcutaneous formulation of infliximab, Remsima SC, and its U.S. brand name, Jimpentra, recorded combined sales of 456.2 billion won in the first half of this year, bringing the company closer to its goal of achieving annual sales of 1 trillion won.
By product, Remsima SC, which is sold in Europe and South Korea, generated 356.7 billion won, a 20.3% increase compared to the same period last year. The U.S.-exclusive product, Jimpentra, saw sales soar to 99.5 billion won, a 176.4% increase. Celltrion explained that the growth, previously centered in Europe, is now diversifying with the rapid growth in the U.S.
According to data from the pharmaceutical market research firm IQVIA, Remsima SC achieved a market share of approximately 32% in the five major European countries (EU5: Germany, France, Italy, Spain, and the UK) as of the first quarter of this year, marking the highest quarterly share since its launch in Europe in 2020. Germany had the highest share at 49%, meaning one in two patients receiving infliximab treatment was prescribed Remsima SC. France (35%) and Italy (31%) also showed broadening prescription bases.
The growth of Remsima SC can be attributed to Celltrion's dual formulation strategy, which offers both intravenous (IV) and subcutaneous (SC) options. This allows healthcare providers to choose between hospital-administered IV and patient self-administered SC based on the patient's condition and treatment environment. This strategy has led to a trend where patients initially treated with Remsima transition to Remsima SC during maintenance therapy.
Additionally, the European infliximab market has expanded at an average annual growth rate of about 9% from 2019 to 2024, providing a favorable environment for growth. Infliximab has been used for over 20 years to treat autoimmune diseases such as inflammatory bowel disease (IBD).
In the U.S., Jimpentra, which is approved as a new drug in the subcutaneous formulation, saw sales in the first half of the year increase by 176.4% compared to the same period last year. Unlike the existing IV formulation, which requires patients to visit a hospital for administration, Jimpentra allows patients to self-inject in their preferred location, enhancing treatment convenience. Celltrion plans to expand its marketing to healthcare providers and patients based on insurance reimbursement and distribution networks in the U.S. to continue growing prescriptions and sales.
In addition to expanding prescriptions and supply in existing markets, Celltrion is also entering new markets. The company plans to launch Remsima SC in Japan, a key market in Asia, next year. It will also gradually expand sales in Latin America according to the approval schedules of individual countries.
A company official stated, "With stable growth in Europe and rapid growth in the U.S., our growth trajectory has diversified. We will continue to expand prescriptions in existing markets and proceed smoothly with the launches in Japan and Latin America to develop the Remsima SC product line into our second product to achieve annual sales of 1 trillion won, following Remsima."
By product, Remsima SC, which is sold in Europe and South Korea, generated 356.7 billion won, a 20.3% increase compared to the same period last year. The U.S.-exclusive product, Jimpentra, saw sales soar to 99.5 billion won, a 176.4% increase. Celltrion explained that the growth, previously centered in Europe, is now diversifying with the rapid growth in the U.S.
According to data from the pharmaceutical market research firm IQVIA, Remsima SC achieved a market share of approximately 32% in the five major European countries (EU5: Germany, France, Italy, Spain, and the UK) as of the first quarter of this year, marking the highest quarterly share since its launch in Europe in 2020. Germany had the highest share at 49%, meaning one in two patients receiving infliximab treatment was prescribed Remsima SC. France (35%) and Italy (31%) also showed broadening prescription bases.
The growth of Remsima SC can be attributed to Celltrion's dual formulation strategy, which offers both intravenous (IV) and subcutaneous (SC) options. This allows healthcare providers to choose between hospital-administered IV and patient self-administered SC based on the patient's condition and treatment environment. This strategy has led to a trend where patients initially treated with Remsima transition to Remsima SC during maintenance therapy.
Additionally, the European infliximab market has expanded at an average annual growth rate of about 9% from 2019 to 2024, providing a favorable environment for growth. Infliximab has been used for over 20 years to treat autoimmune diseases such as inflammatory bowel disease (IBD).
In the U.S., Jimpentra, which is approved as a new drug in the subcutaneous formulation, saw sales in the first half of the year increase by 176.4% compared to the same period last year. Unlike the existing IV formulation, which requires patients to visit a hospital for administration, Jimpentra allows patients to self-inject in their preferred location, enhancing treatment convenience. Celltrion plans to expand its marketing to healthcare providers and patients based on insurance reimbursement and distribution networks in the U.S. to continue growing prescriptions and sales.
In addition to expanding prescriptions and supply in existing markets, Celltrion is also entering new markets. The company plans to launch Remsima SC in Japan, a key market in Asia, next year. It will also gradually expand sales in Latin America according to the approval schedules of individual countries.
A company official stated, "With stable growth in Europe and rapid growth in the U.S., our growth trajectory has diversified. We will continue to expand prescriptions in existing markets and proceed smoothly with the launches in Japan and Latin America to develop the Remsima SC product line into our second product to achieve annual sales of 1 trillion won, following Remsima."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.